Tumor News and Research

RSS

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.

5 Dec 2013

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.

5 Dec 2013

New study provides novel stem cell based, tissue engineered construct which can repair damaged bone

Researchers at the Department of Orthopaedics, of the Second Affiliated Hospital of Xi'an Jiaotong University Health Science Center, led by Dr. Kunzheng Wang and Dr. Pei Yang have developed a novel biomimetic tissue engineered bone graft based on rabbit adipose derived stem cells (rASCs), collagen I and a porous beta-tricalcium phosphate (β-TCP) scaffold.

5 Dec 2013

New method for counting tumor-fighting cells to predict ovarian cancer

One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.

5 Dec 2013

Senesco completes cohort 3 of SNS01-T Phase 1b/2a trial for multiple myeloma and lymphoma treatment

Senesco Technologies, Inc. reported today the completion of cohort 3 of its Phase 1b/2a clinical trial for its drug, SNS01-T, for the treatment of multiple myeloma and lymphoma. The Company has also received approval from its Data Review Committee to proceed to cohort 4, which is expected to require six evaluable patients.

5 Dec 2013

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.

5 Dec 2013

UCLA researchers discover how prostate cancer stem cells evolve as the disease grows

UCLA researchers have discovered how prostate cancer stem cells evolve as the disease progresses, a finding that could help point the way to more highly targeted therapies.

4 Dec 2013

BIDMC study shows carbon monoxide may have a role to play in treating cancer

In recent years, research has suggested that carbon monoxide, the highly toxic gas emitted from auto exhausts and faulty heating systems, can be used to treat certain inflammatory medical conditions. Now a study led by a research team at Beth Israel Deaconess Medical Center (BIDMC) shows for the first time that carbon monoxide may also have a role to play in treating cancer.

4 Dec 2013

Roche signs research collaboration and licensing agreement with Molecular Partners

Roche and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners' DARPin biologics conjugated to toxic agents developed at Roche for the treatment of cancer.

4 Dec 2013

Genetic mutation linked to excess risk of lethal prostate cancer in obese patients

Obesity is associated with a worse prostate cancer prognosis among men whose tumors contain a specific genetic mutation, suggest results from a new study led by Harvard School of Public Health, Dana-Farber Cancer Institute and Brigham and Women's Hospital researchers.

4 Dec 2013

MR-guided ultrasound may offer safe and effective treatment for breast cancer

A technique that uses focused ultrasound under magnetic resonance guidance to heat and destroy tumors may offer a safe and effective treatment for breast cancer, according to research being presented today at the annual meeting of the Radiological Society of North America.

4 Dec 2013

18F-FDOPA imaging can help distinguish radiation-induced lesions in patients with brain metastases

Imaging with the molecular imaging tracer 18F-FDOPA can help distinguish radiation-induced lesions from new tumor growth in patients who have been treated with radiation for brain metastases, according to new research published in The Journal of Nuclear Medicine. Using this amino acid tracer, researchers found that physicians could accurately differentiate the two types of lesions 83 percent of the time. Progression-free survival could also be predicted through evaluating the 18F-FDOPA imaging results.

4 Dec 2013

Study finds two distinct subtypes in pediatric diffuse intrinsic pontine gliomas

Children's National researcher, Javad Nazarian, PhD, authored a new study entitled, "Comparative Multidimensional Molecular Analyses of Pediatric Diffuse Intrinsic Pontine Glioma Reveals Distinct Molecular Subtypes." The study found, for the first time, two distinct subtypes in pediatric diffuse intrinsic pontine gliomas.

4 Dec 2013

Cell Therapeutics concludes agreement with GKV-SV regarding reimbursement price of PIXUVRI

Cell Therapeutics, Inc. (CTI) announced today that it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany for PIXUVRI® (pixantrone).

4 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children's Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

4 Dec 2013

Findings could have important implications for personalized treatment of colon cancer

A common observation in oncology is the phenomenon that a patient with a tumor receives a drug and responds very well, but after a few months the cancer comes back and is now resistant to previously administered chemotherapy. What happened? Many mechanisms contribute to explain this effect called "acquired resistance", but today the group Manel Esteller, Director of Epigenetics and Cancer Biology at the Bellvitge Biomedical Research Institute, ICREA researcher and Professor of Genetics at the University of Barcelona, describes in the official Journal of the National Cancer Research Center in the United States, The Journal of The National Cancer Institute, the existence of epigenetic differences that explain the lack of response of the tumor recurs.

4 Dec 2013

A new approach for treating colorectal cancer

Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse.

4 Dec 2013

Scientists receive $12.5M NIH grant to continue research on targeted therapies for melanoma

Despite recent advances in therapy, melanoma remains the deadliest, most aggressive form of skin cancer as incidence rates continue to climb. Now, a team of melanoma scientists from The Wistar Institute and the University of Pennsylvania received a $12.5 M, five-year program project grant (P01) from the National Institutes of Health to continue trailblazing research on targeted therapies in melanoma.

4 Dec 2013

Clinicians ‘nihilistic’ toward lung cancer patients

Clinicians tend to view their lung cancer patients more negatively than patients with other solid tumors, study findings indicate.

3 Dec 2013

Tumor News and Research

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

New study provides novel stem cell based, tissue engineered construct which can repair damaged bone

New method for counting tumor-fighting cells to predict ovarian cancer

Senesco completes cohort 3 of SNS01-T Phase 1b/2a trial for multiple myeloma and lymphoma treatment

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

UCLA researchers discover how prostate cancer stem cells evolve as the disease grows

BIDMC study shows carbon monoxide may have a role to play in treating cancer

Roche signs research collaboration and licensing agreement with Molecular Partners

Genetic mutation linked to excess risk of lethal prostate cancer in obese patients

MR-guided ultrasound may offer safe and effective treatment for breast cancer

18F-FDOPA imaging can help distinguish radiation-induced lesions in patients with brain metastases

Study finds two distinct subtypes in pediatric diffuse intrinsic pontine gliomas

Cell Therapeutics concludes agreement with GKV-SV regarding reimbursement price of PIXUVRI

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

Findings could have important implications for personalized treatment of colon cancer

A new approach for treating colorectal cancer

Scientists receive $12.5M NIH grant to continue research on targeted therapies for melanoma

Clinicians ‘nihilistic’ toward lung cancer patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News